X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abridged index medicus (2) 2
aged (2) 2
cancer (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
carcinoma, non-small-cell lung - secondary (2) 2
chemotherapy (2) 2
female (2) 2
humans (2) 2
index medicus (2) 2
interactive systems (2) 2
kinases (2) 2
lung cancer (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - pathology (2) 2
male (2) 2
medicine, general & internal (2) 2
metastasis (2) 2
middle aged (2) 2
motivation (2) 2
mutation (2) 2
patients (2) 2
survival (2) 2
adult (1) 1
advanced nsclc (1) 1
af-001jp (1) 1
aged, 80 and over (1) 1
analysis (1) 1
anaplastic lymphoma kinase (1) 1
anaplastic lymphoma kinase - drug effects (1) 1
anaplastic lymphoma kinase - genetics (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - blood (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
apoptosis (1) 1
audio frequencies (1) 1
b7-h1 antigen - metabolism (1) 1
bevacizumab (1) 1
brain neoplasms - secondary (1) 1
cancer therapies (1) 1
carbazoles - adverse effects (1) 1
carbazoles - blood (1) 1
carbazoles - therapeutic use (1) 1
carboplatin (1) 1
carcinoma, non-small-cell lung - enzymology (1) 1
carcinoma, non-small-cell lung - metabolism (1) 1
care and treatment (1) 1
cell survival (1) 1
central nervous system (1) 1
ch5424802 (1) 1
crizotinib (1) 1
cut-off (1) 1
data processing (1) 1
death (1) 1
disease-free survival (1) 1
drug administration schedule (1) 1
drug dosages (1) 1
effectiveness (1) 1
epidermal growth factor receptors (1) 1
far east - epidemiology (1) 1
funding (1) 1
further section · weitere sektionen (1) 1
gefitinib (1) 1
genes, erbb-1 - drug effects (1) 1
genes, erbb-1 - genetics (1) 1
group dynamics (1) 1
histology (1) 1
hyperthyroidism (1) 1
hypothyroidism (1) 1
inhibitors (1) 1
internal medicine (1) 1
kaplan-meier estimate (1) 1
life expectancy (1) 1
life span (1) 1
ligands (1) 1
lung neoplasms - enzymology (1) 1
lung neoplasms - metabolism (1) 1
lung neoplasms - secondary (1) 1
lymphoma (1) 1
lymphomas (1) 1
medical centres (1) 1
medical colleges (1) 1
medical services (1) 1
men (1) 1
metastases (1) 1
neoplasm grading (1) 1
neoplasm metastasis - pathology (1) 1
nivolumab (1) 1
oncology (1) 1
paclitaxel (1) 1
pd-l1 protein (1) 1
pembrolizumab (1) 1
pharmaceutical industry (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
by Mok, Tony and Mok, Tony S K and Wu, Yilong and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Kowalski, Dariusz and Cho, Byoung Chul and Turna, Hande and Turna, Hande Z and Castro, Hugo and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Zhang, Li and Zhang, Xin and Kush, Debra and Lopes, Valeria and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Xi and Chen, Gongyan and Cheng, Ying and Cheng, Susanna and Cherciu, Nelly and Chiu, Chao-Hua and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Yong and He, Jianxing and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a... 
MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | BEVACIZUMAB | CRIZOTINIB | NIVOLUMAB | PACLITAXEL | Genes, erbB-1 - drug effects | Lung Neoplasms - drug therapy | Translocation, Genetic | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lung Neoplasms - metabolism | Middle Aged | Far East - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Anaplastic Lymphoma Kinase - genetics | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Lung Neoplasms - secondary | Female | Carcinoma, Non-Small-Cell Lung - pathology | Anaplastic Lymphoma Kinase - drug effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Genes, erbB-1 - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Disease-Free Survival | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Metastasis - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Slopes | Lung cancer | Oncology | Kinases | Cancer therapies | Metastases | Pembrolizumab | Randomization | Motivation | Platinum | Risk assessment | Population | Translocation | Cell survival | Life expectancy | Epidermal growth factor receptors | Hyperthyroidism | Histology | Hypothyroidism | Survival | Patients | Medical centres | Life span | Interactive systems | PD-L1 protein | Men | Ligands | Tumors | Apoptosis
Journal Article
Oncology Research and Treatment, ISSN 2296-5270, 05/2012, Volume 35, Issue 5, pp. 316 - 317
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.